Gender Disparities in Statin Use Among HIV Patients

Why It Matters

Statin underuse in women with HIV leaves a vulnerable population exposed to preventable heart disease, widening existing health inequities and increasing long‑term healthcare costs.

Key Takeaways

• Women with HIV 30% less likely to receive statins
• Disparity remains after adjusting for risk factors
• Gap most pronounced in high ASCVD‑risk patients
• Prescribing bias linked to underrecognition of female risk
• Potential cost‑lier complications from untreated cardiovascular disease

Pulse Analysis

The gender gap in statin therapy among people living with HIV underscores a broader challenge: integrating cardiovascular risk management into HIV care. While antiretroviral treatment has dramatically improved survival, clinicians often prioritize viral suppression over comorbid conditions. This study highlights that women, who already face higher rates of dyslipidemia and inflammation, are systematically less likely to receive evidence‑based lipid‑lowering drugs. Recognizing this oversight is the first step toward aligning HIV treatment protocols with contemporary cardiovascular guidelines.

Understanding the root causes of the disparity requires examining both clinical workflows and patient‑level factors. Providers may underestimate cardiovascular risk in women due to historic trial data that underrepresented female participants. Additionally, women with HIV frequently encounter socioeconomic barriers, such as limited access to specialty care and medication affordability, which can deter statin initiation. Addressing these issues calls for targeted education, decision‑support tools that flag high‑risk patients, and policies that reduce out‑of‑pocket costs for essential preventive medications.

The implications extend beyond individual health outcomes to the broader healthcare system. Untreated dyslipidemia in women with HIV can lead to higher rates of myocardial infarction, stroke, and associated hospitalizations, inflating long‑term expenditures. Payers and policymakers should incentivize comprehensive risk assessments and equitable prescribing practices. By closing the gender gap in statin use, the medical community can improve cardiovascular survival for a population that has already benefited from advances in HIV therapy, reinforcing the principle of holistic, gender‑sensitive care.